Xilis

Closed

Revolutionizing Drug Discovery and Development with Patient-Derived MicroOrganoSpheres®

Durham, United States · Founded 2019 · $111.0M raised

Employees
51–200
Founded
2019
Business Model
B2B
Website
xilis.com
Total Funding
$111.0M
Last Round
$19.0M Series AApr 2025
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Xilis develops advanced patient-derived organoid technology to accelerate pharmaceutical development and improve cancer treatment outcomes. The company's proprietary MicroOrganoSphere® (MOS) platform creates 3D micro-tumor models that preserve the cellular composition, genetic alterations, immune microenvironment, and histopathology of primary patient tissue. These models enable more accurate drug efficacy predictions and reduce risk throughout the drug discovery and development lifecycle—from initial discovery through clinical trials—spanning immuno-oncology, chemotherapy, and cell therapy applications. The platform integrates automated model creation, customizable assays, and AI-powered analytics to support both precision oncology diagnostics and pharmaceutical R&D partnerships.

Summary

Xilis is a Biotech company based in Durham, United States, founded in 2019. It has raised $111.0M in total across 4 rounds, most recently a $19.0M Series A round in Apr 2025. Investors include Felicis Ventures, Fpv Ventures and Mubadala Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AApr 2025
$19.0M

Sign up to see all 4 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Treeline Biosciences

Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...

Watertown, United States51–200Biotech, Drug Discovery
Extension RoundTotal funding$821.8MSep 2025
LifeMine

Therapeutics company working in drug discovery and development using fungi with genomics approach...

Watertown, United States51–200Biotech, Drug Discovery
Venture RoundTotal funding$816.0MAug 2026
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Chai Discovery

Chai Discovery builds frontier AI to predict and reprogram interactions between biochemical molec...

San Francisco, United States11–50Artificial Intelligence, Biotech
Series CTotal funding$630.0MJul 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Xilis on Indexed.vc
<a href="https://indexed.vc/companies/xilis"><img src="https://indexed.vc/api/badge/company/xilis" alt="Xilis on Indexed.vc" width="260" height="76" /></a>